Compare Lemonade Inc (LMND) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Viatris Inc — how do they compare? Lemonade Inc trades at $67.81 (market cap $5.18B), while Viatris Inc trades at $17 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 3.8× Lemonade Inc's market cap, and Viatris Inc pays a 2.83% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| LMND | VTRS | |
|---|---|---|
Market Cap | $5.18B | $19.79B |
Sector | Financials | Health |
52-Week High | $96.57 | $17.39 |
52-Week Low | $36.28 | $8.74 |
Enterprise Value | $5.01B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $67.47, up 0.43% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. Revenue growth is accelerating, reaching $738 million in 2025, while net losses are narrowing to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, supporting optimism for future profitability.
The outlook is mixed: strong top-line growth and path to EBITDA positivity offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus targets $69.60, with 33% buy ratings, reflecting cautious optimism amid execution challenges in the competitive insurance sector.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
